Compass Pathways Highlights Data, Backs 2027 Launch Timeline - Compass Pathways (NASDAQ:CMPS)
benzinga.com/news/health-care/26/07/60312832/compass-pathways-highlights-long-term-data-backs-2027-launch-timeline
Story Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
Similar to This
Previous
STAT Apr 24
FDA to speed up review of three psychedelics as mental health treatments: After Trump administration prodding, FDA offers priority review of psychedelic drugs ...
statnews.com/2026/04/24/trump-psychedelic-drugs-fda-priority-review-mental-health-treatment/
Paid articlePaywall
Barron's Apr 24
FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit.: Compass Pathways, the developer of synthetic psilocybin, announced it had ...
barrons.com/articles/fda-fast-tracks-review-of-some-psychedelic-drugs-6d301e6d
Paid articlePaywall
How Trump Sent Psychedelics-Tied Compass Pathways And Others Flying: Compass Pathways stock surged Monday after President Donald Trump signed an executive order ...
investors.com/news/technology/psychedelic-drugs-executive-order-compass-pathways/
Compass Pathways Cheers Trump Order To Accelerate Access To Psychedlic Drug Treatements: 'Recognizes Prof
benzinga.com/news/health-care/26/04/51903093/compass-pathways-cheers-trump-order-access-psychedlic-drug-treatements
Barron's Apr 20
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
barrons.com/articles/ataibeckley-stock-psychedelic-drugs-trump-3c8a9362
Paid articlePaywall
The FDA could approve a key component of magic mushrooms as a depression treatment
qz.com/compass-pathways-psilocybin-fda-clinical-trial
Compass Pathways stock soars after positive Phase 3 trial results: Compass Pathways stock soars after positive Phase 3 trial results
investing.com/news/stock-market-news/compass-pathways-stock-soars-after-positive-phase-3-trial-results-93CH-4508978
STAT Feb 17
Compass says its psilocybin drug helped patients with severe depression in two trials
statnews.com/2026/02/17/compass-pathways-comp360-psilocybin-severe-depression-trial-results/
Paid articlePaywall
The New Psychedelics: One Dose, Eight Hours, a Therapist on Standby: Biotech firms developing magic-mushroom-based treatments are trying to shed their ...
bloomberg.com/news/articles/2025-12-26/psilocybin-aims-for-mainstream-as-a-psychedelic-treatment-for-depression
Paid articlePaywall
Compass Pathways to expedite launch of its experimental depression therapy: Drug developer Compass Pathways said on Tuesday it is pulling forward the expected ...
reuters.com/business/healthcare-pharmaceuticals/compass-pathways-expedite-launch-timing-its-experimental-depression-therapy-2025-11-04/
Next